Corticosteroids for severe CAP: the pros - Critical Care Science (CCS)
Severe community-acquired pneumonia (CAP) occurs in approximately 10% of hospitalized patients with CAP, and it still carries a high morbidity and mortality. In a multicenter study on severe pneumococcal CAP, the mortality of this population was 29%, with high rates of patients requiring mechanical ventilation and a shock.() Patients with severe CAP might die despite early and adequate antibiotic treatment, which is probably partially due to an imbalanced and disproportionate local and systemic inflammatory response that contributes to the impairment of alveolar gas-exchange, sepsis and end-organ dysfunction.()
There is no doubt that systemic adjunctive corticosteroid therapy attenuates the local and systemic inflammatory response() and may potentially decrease acute respiratory distress syndrome, sepsis and mortality. In a model of Pseudomonas aeruginosa in mechanically ventilated piglets, we observed a lower lung bacterial burden and less severe histological pneumonia in piglets that were treated with corticosteroids plus antibiotics.() In humans, several randomized controlled trials (RCTs) have been performed, with the participants largely being hospitalized, non-severe CAP patients. The results of these trials have been negative() or have demonstrated a reduction in the length of stay() or in the period required to reach clinical stability.() Four previous studies have been performed on severe CAP.(–) A meta-analysis that included some of these studies()demonstrated that the pooled effect of steroids in severe CAP is a reduction in mortality.
[…]
Search
Search in:
Search
Search in:
Severe community-acquired pneumonia (CAP) occurs in approximately 10% of hospitalized patients with CAP, and it still carries a high morbidity and mortality. In a multicenter study on severe pneumococcal CAP, the mortality of this population was 29%, with high rates of patients requiring mechanical ventilation and a shock.() Patients with severe CAP might die despite early and adequate antibiotic treatment, which is probably partially due to an imbalanced and disproportionate local and systemic inflammatory response that contributes to the impairment of alveolar gas-exchange, sepsis and end-organ dysfunction.()
There is no doubt that systemic adjunctive corticosteroid therapy attenuates the local and systemic inflammatory response() and may potentially decrease acute respiratory distress syndrome, sepsis and mortality. In a model of Pseudomonas aeruginosa in mechanically ventilated piglets, we observed a lower lung bacterial burden and less severe histological pneumonia in piglets that were treated with corticosteroids plus antibiotics.() In humans, several randomized controlled trials (RCTs) have been performed, with the participants largely being hospitalized, non-severe CAP patients. The results of these trials have been negative() or have demonstrated a reduction in the length of stay() or in the period required to reach clinical stability.() Four previous studies have been performed on severe CAP.(-) A meta-analysis that included some of these studies()demonstrated that the pooled effect of steroids in severe CAP is a reduction in mortality.
[...]
Comments